SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.

Shenzhen Chipscreen Biosciences Co., Ltd.

688321

CNE100003LW0

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-03-06			5-day change	1st Jan Change
30.45 ^CNY	+2.39%		-6.60%	+4.21%

Feb. 26	Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Jan. 27	Shenzhen Chipscreen Biosciences Expects Return to Profitability in 2025	MT

Shenzhen Chipscreen Biosciences Expects Return to Profitability in 2025

Published on 01/27/2026 at 06:34 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shenzhen Chipscreen Biosciences Co., Ltd.

Feb. 26	Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Jan. 27	Shenzhen Chipscreen Biosciences Expects Return to Profitability in 2025	MT
Jan. 09	Chipscreen Biosciences Gets Nod for Xioronni Capsules' Clinical Trials	MT
Jan. 08	Shenzhen Chipscreen Biosciences Gets Macao Marketing Approval for Cancer Drug	MT
Jan. 02	Chinese Drug Regulator Accepts Clinical Trial Application of Chipscreen Biosciences' Unit for CS08399 Tablets	MT
Dec. 23	Tranche Update on Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback Plan announced on October 31, 2025.	CI
Dec. 22	Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback announced on October 31, 2025, has closed with 538,200 shares, representing 0.13% for CNY 15 million.	CI
Nov. 07	Shenzhen Chipscreen Biosciences Gets Clinical Trial Approval for Pancreatic Cancer Treatment	MT
25-10-31	Shenzhen Chipscreen Biosciences Co., Ltd. announces an Equity Buyback for CNY 15 million worth of its shares.	CI
25-10-30	Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-29	Shenzhen Chipscreen Biosciences Co., Ltd. authorizes a Buyback Plan.	CI
25-09-10	Chipscreen Biosciences' shareholder to unload stake in co	RE
25-08-25	Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-01	Chipscreen Bio's US Unit Gets FDA Nod for Anti-Brain Tumor Drug	MT
25-07-31	FDA IND nods for Chipscreen's brain-penetrant Aurora B inhibitor CS231295 tablet boosts trials	RE

Chart Shenzhen Chipscreen Biosciences Co., Ltd.

Duration

Period

Chart Shenzhen Chipscreen Biosciences Co., Ltd.

688321: Dynamic Chart

Shenzhen Chipscreen Biosciences Co Ltd is a China-based company mainly engaged in the research and development of original innovative drugs. The Company focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The Company's main products include Chidamide, Siglitazone, Cioroni and CS12192. The Company mainly conducts its businesses in the domestic market.

Employees

1,060

Sector

Pharmaceuticals

Calendar

Mar. 31 - Earnings release - Annual 2025

More about the company